Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.

de Wet TJ, Warner DF, Mizrahi V.

Acc Chem Res. 2019 Aug 20;52(8):2340-2348. doi: 10.1021/acs.accounts.9b00275. Epub 2019 Jul 30.

2.

Synthesis and Structure-Activity relationship of 1-(5-isoquinolinesulfonyl)piperazine analogues as inhibitors of Mycobacterium tuberculosis IMPDH.

Singh V, Pacitto A, Donini S, Ferraris DM, Boros S, Illyés E, Szokol B, Rizzi M, Blundell TL, Ascher DB, Pato J, Mizrahi V.

Eur J Med Chem. 2019 Jul 15;174:309-329. doi: 10.1016/j.ejmech.2019.04.027. Epub 2019 Apr 15.

PMID:
31055147
3.

Expanding the anti-TB arsenal.

Mizrahi V, Warner DF.

Science. 2019 Feb 1;363(6426):457-458. doi: 10.1126/science.aaw5224. No abstract available.

PMID:
30705174
4.

Transmission of drug-resistant tuberculosis in HIV-endemic settings.

Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A.

Lancet Infect Dis. 2019 Mar;19(3):e77-e88. doi: 10.1016/S1473-3099(18)30537-1. Epub 2018 Dec 13. Review. Erratum in: Lancet Infect Dis. 2019 Mar 6;:.

5.

The Coming of Age of Drug-Susceptibility Testing for Tuberculosis.

Cox H, Mizrahi V.

N Engl J Med. 2018 Oct 11;379(15):1474-1475. doi: 10.1056/NEJMe1811861. Epub 2018 Sep 26. No abstract available.

6.

Death of Mycobacterium tuberculosis by l-arginine starvation.

Mizrahi V, Warner DF.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9658-9660. doi: 10.1073/pnas.1813587115. Epub 2018 Sep 6. No abstract available.

7.

Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment.

Koch A, Cox H, Mizrahi V.

Curr Opin Pharmacol. 2018 Oct;42:7-15. doi: 10.1016/j.coph.2018.05.013. Epub 2018 Jun 6. Review.

8.

Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients.

Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, Mizrahi V, Bryden W, Call C, Patel S, Warner D, Wood R.

Version 2. Gates Open Res. 2018 Jun 8 [revised 2018 Jan 1];1:11. doi: 10.12688/gatesopenres.12758.2. eCollection 2017.

9.

Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents.

Chacko S, Boshoff HIM, Singh V, Ferraris DM, Gollapalli DR, Zhang M, Lawson AP, Pepi MJ, Joachimiak A, Rizzi M, Mizrahi V, Cuny GD, Hedstrom L.

J Med Chem. 2018 Jun 14;61(11):4739-4756. doi: 10.1021/acs.jmedchem.7b01839. Epub 2018 May 30.

10.

Mycobacterium tuberculosis.

Koch A, Mizrahi V.

Trends Microbiol. 2018 Jun;26(6):555-556. doi: 10.1016/j.tim.2018.02.012. Epub 2018 Mar 23.

PMID:
29580884
11.

Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.

Trapero A, Pacitto A, Singh V, Sabbah M, Coyne AG, Mizrahi V, Blundell TL, Ascher DB, Abell C.

J Med Chem. 2018 Apr 12;61(7):2806-2822. doi: 10.1021/acs.jmedchem.7b01622. Epub 2018 Mar 23.

12.

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, Soares de Melo C, Feng TS, Street LJ, Chibale K, Warner DF, Mizrahi V, Epemolu O, Scullion P, Ellis L, Riley J, Shishikura Y, Ferguson L, Osuna-Cabello M, Read KD, Green SR, Lamprecht DA, Finin PM, Steyn AJC, Ioerger TR, Sacchettini J, Rhee KY, Arora K, Barry CE 3rd, Wyatt PG, Boshoff HIM.

ACS Infect Dis. 2018 Jun 8;4(6):954-969. doi: 10.1021/acsinfecdis.7b00275. Epub 2018 Mar 26.

13.

Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.

Evans JC, Mizrahi V.

Curr Opin Microbiol. 2018 Oct;45:39-46. doi: 10.1016/j.mib.2018.02.006. Epub 2018 Feb 23. Review.

PMID:
29482115
14.

Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.

Reiche MA, Warner DF, Mizrahi V.

Front Mol Biosci. 2017 Nov 14;4:75. doi: 10.3389/fmolb.2017.00075. eCollection 2017. Review.

15.

Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE 3rd, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.

J Med Chem. 2017 Dec 28;60(24):10118-10134. doi: 10.1021/acs.jmedchem.7b01347. Epub 2017 Dec 7.

16.

DNA Replication Fidelity in the Mycobacterium tuberculosis Complex.

Warner DF, Rock JM, Fortune SM, Mizrahi V.

Adv Exp Med Biol. 2017;1019:247-262. doi: 10.1007/978-3-319-64371-7_13. Review.

PMID:
29116639
17.

N-Acetylglucosamine-1-Phosphate Transferase, WecA, as a Validated Drug Target in Mycobacterium tuberculosis.

Huszár S, Singh V, Polčicová A, Baráth P, Barrio MB, Lagrange S, Leblanc V, Nacy CA, Mizrahi V, Mikušová K.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01310-17. doi: 10.1128/AAC.01310-17. Print 2017 Nov.

18.

Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LAT, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01429-17. doi: 10.1128/AAC.01429-17. Print 2017 Sep. No abstract available.

19.

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c.

Moosa A, Lamprecht DA, Arora K, Barry CE 3rd, Boshoff HIM, Ioerger TR, Steyn AJC, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01338-17. doi: 10.1128/AAC.01338-17. Print 2017 Oct.

20.

The Influence of HIV on the Evolution of Mycobacterium tuberculosis.

Koch AS, Brites D, Stucki D, Evans JC, Seldon R, Heekes A, Mulder N, Nicol M, Oni T, Mizrahi V, Warner DF, Parkhill J, Gagneux S, Martin DP, Wilkinson RJ.

Mol Biol Evol. 2017 Jul 1;34(7):1654-1668. doi: 10.1093/molbev/msx107.

21.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.

Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC.

Mol Microbiol. 2017 Jan;103(1):13-25. doi: 10.1111/mmi.13535. Epub 2016 Oct 29.

22.

The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.

Singh V, Donini S, Pacitto A, Sala C, Hartkoorn RC, Dhar N, Keri G, Ascher DB, Mondésert G, Vocat A, Lupien A, Sommer R, Vermet H, Lagrange S, Buechler J, Warner DF, McKinney JD, Pato J, Cole ST, Blundell TL, Rizzi M, Mizrahi V.

ACS Infect Dis. 2017 Jan 13;3(1):5-17. doi: 10.1021/acsinfecdis.6b00102. Epub 2016 Sep 8.

23.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

24.

Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.

Evans JC, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D, Boshoff HI, Rhee KY, Barry CE 3rd, Mizrahi V.

ACS Infect Dis. 2016 Dec 9;2(12):958-968. Epub 2016 Oct 5.

25.

Identification and validation of novel drug targets in Mycobacterium tuberculosis.

Singh V, Mizrahi V.

Drug Discov Today. 2017 Mar;22(3):503-509. doi: 10.1016/j.drudis.2016.09.010. Epub 2016 Sep 17. Review.

PMID:
27649943
26.

Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.

Naran K, Moosa A, Barry CE 3rd, Boshoff HI, Mizrahi V, Warner DF.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6748-6757. doi: 10.1128/AAC.01178-16. Print 2016 Nov.

27.

Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis.

Djaout K, Singh V, Boum Y, Katawera V, Becker HF, Bush NG, Hearnshaw SJ, Pritchard JE, Bourbon P, Madrid PB, Maxwell A, Mizrahi V, Myllykallio H, Ekins S.

Sci Rep. 2016 Jun 10;6:27792. doi: 10.1038/srep27792.

28.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.

Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M.

PLoS Med. 2016 Mar 2;13(3):e1001965. doi: 10.1371/journal.pmed.1001965. eCollection 2016 Mar. Review. No abstract available.

29.

Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC).

Wood R, Morrow C, Barry CE 3rd, Bryden WA, Call CJ, Hickey AJ, Rodes CE, Scriba TJ, Blackburn J, Issarow C, Mulder N, Woodward J, Moosa A, Singh V, Mizrahi V, Warner DF.

PLoS One. 2016 Jan 25;11(1):e0146658. doi: 10.1371/journal.pone.0146658. eCollection 2016.

30.

The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.

Evans JC, Mizrahi V.

Front Microbiol. 2015 Aug 4;6:812. doi: 10.3389/fmicb.2015.00812. eCollection 2015. Review.

31.

Nucleotide Metabolism and DNA Replication.

Warner DF, Evans JC, Mizrahi V.

Microbiol Spectr. 2014 Oct;2(5). doi: 10.1128/microbiolspec.MGM2-0001-2013. Review.

PMID:
26104350
32.

Targeted gene knockout and essentiality testing by homologous recombination.

Gopinath K, Warner DF, Mizrahi V.

Methods Mol Biol. 2015;1285:131-49. doi: 10.1007/978-1-4939-2450-9_8.

PMID:
25779314
33.

Cleavage of the moaX-encoded fused molybdopterin synthase from Mycobacterium tuberculosis is necessary for activity.

Narrandes NC, Machowski EE, Mizrahi V, Kana BD.

BMC Microbiol. 2015 Feb 6;15:22. doi: 10.1186/s12866-015-0355-2.

34.

The complex mechanism of antimycobacterial action of 5-fluorouracil.

Singh V, Brecik M, Mukherjee R, Evans JC, Svetlíková Z, Blaško J, Surade S, Blackburn J, Warner DF, Mikušová K, Mizrahi V.

Chem Biol. 2015 Jan 22;22(1):63-75. doi: 10.1016/j.chembiol.2014.11.006. Epub 2014 Dec 24.

35.

Diversity and disease pathogenesis in Mycobacterium tuberculosis.

Warner DF, Koch A, Mizrahi V.

Trends Microbiol. 2015 Jan;23(1):14-21. doi: 10.1016/j.tim.2014.10.005. Epub 2014 Nov 10. Review.

PMID:
25468790
36.

Translating genomics research into control of tuberculosis: lessons learned and future prospects.

Warner DF, Mizrahi V.

Genome Biol. 2014 Nov 7;15(11):514. doi: 10.1186/s13059-014-0514-z. Review.

37.

bis-Molybdopterin guanine dinucleotide is required for persistence of Mycobacterium tuberculosis in guinea pigs.

Williams MJ, Shanley CA, Zilavy A, Peixoto B, Manca C, Kaplan G, Orme IM, Mizrahi V, Kana BD.

Infect Immun. 2015 Feb;83(2):544-50. doi: 10.1128/IAI.02722-14. Epub 2014 Nov 17.

38.

Shortening treatment for tuberculosis--to basics.

Warner DF, Mizrahi V.

N Engl J Med. 2014 Oct 23;371(17):1642-3. doi: 10.1056/NEJMe1410977. No abstract available.

39.

Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LA, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2014 Nov;58(11):6962-5. doi: 10.1128/AAC.03486-14. Epub 2014 Aug 25. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.

40.

The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?

Koch A, Mizrahi V, Warner DF.

Emerg Microbes Infect. 2014 Mar;3(3):e17. doi: 10.1038/emi.2014.17. Epub 2014 Mar 12. Review.

41.

Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase.

Xu Z, Yin W, Martinelli LK, Evans J, Chen J, Yu Y, Wilson DJ, Mizrahi V, Qiao C, Aldrich CC.

Bioorg Med Chem. 2014 Mar 1;22(5):1726-35. doi: 10.1016/j.bmc.2014.01.017. Epub 2014 Jan 23.

42.

Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents.

Mjambili F, Njoroge M, Naran K, De Kock C, Smith PJ, Mizrahi V, Warner D, Chibale K.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):560-4. doi: 10.1016/j.bmcl.2013.12.022. Epub 2013 Dec 12.

PMID:
24373723
43.

A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis.

Kumar A, Casey A, Odingo J, Kesicki EA, Abrahams G, Vieth M, Masquelin T, Mizrahi V, Hipskind PA, Sherman DR, Parish T.

PLoS One. 2013 Nov 7;8(11):e72786. doi: 10.1371/journal.pone.0072786. eCollection 2013.

44.

Vitamin B(12) metabolism in Mycobacterium tuberculosis.

Gopinath K, Moosa A, Mizrahi V, Warner DF.

Future Microbiol. 2013 Nov;8(11):1405-18. doi: 10.2217/fmb.13.113. Review.

PMID:
24199800
45.

Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis.

Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE 3rd, Sherman DR, Parish T, Sacchettini JC.

PLoS One. 2013 Sep 23;8(9):e75245. doi: 10.1371/journal.pone.0075245. eCollection 2013.

46.

Complex genetics of drug resistance in Mycobacterium tuberculosis.

Warner DF, Mizrahi V.

Nat Genet. 2013 Oct;45(10):1107-8. doi: 10.1038/ng.2769.

PMID:
24071843
47.

DNA metabolism in mycobacterial pathogenesis.

Warner DF, Tønjum T, Mizrahi V.

Curr Top Microbiol Immunol. 2013;374:27-51. doi: 10.1007/82_2013_328. Review.

PMID:
23633106
48.

A vitamin B₁₂ transporter in Mycobacterium tuberculosis.

Gopinath K, Venclovas C, Ioerger TR, Sacchettini JC, McKinney JD, Mizrahi V, Warner DF.

Open Biol. 2013 Feb 13;3(2):120175. doi: 10.1098/rsob.120175.

49.

Molybdenum cofactor: a key component of Mycobacterium tuberculosis pathogenesis?

Williams M, Mizrahi V, Kana BD.

Crit Rev Microbiol. 2014 Feb;40(1):18-29. doi: 10.3109/1040841X.2012.749211. Epub 2013 Jan 15. Review.

PMID:
23317461
50.

Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening.

Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE 3rd, Sherman DR, Boshoff HI, Mizrahi V.

Chem Biol. 2012 Jul 27;19(7):844-54. doi: 10.1016/j.chembiol.2012.05.020.

Supplemental Content

Loading ...
Support Center